News

Call for Abstracts to Present at MHSRS 2021

The call for abstracts to present a poster at this year’s Military Health System Research Symposium (MHSRS) is now open through March 31. They are planning for this year’s conference to be in person. The dates are pending, but usually are in mid- to late-August in Orlando, FL. G2G account managers will reach out separately and in your next check-in call re: assisting with a submission. Details below.

NOTE: DoD-sponsored SARS CoV-2 (COVID-19) related research will be highlighted in dedicated 2021 MHSRS breakout sessions. Oral presentations at these sessions will be by invitation only.

* The Call for Abstracts will be for posters only. COVID-19 related research abstracts submitted to sessions other that those that are focused on COVID-19 will be re-directed to the COVID-19 session leads for poster consideration.

* For 2021, a special MHSRS award category for COVID-19 research will be offered for individuals and teams.

2021 MHSRS Call for Abstracts
February 17, 2021 to March 31, 2021
The deadline will not be extended past 31 March 2021.

How to Submit a 2021 Abstract
(1) Complete the abstract submission form, (2) upload a CV, (3) upload a signed Conflict of Interest (COI) form

The abstract should be no more than 8000 characters in length. There are no format or font restrictions. No embedded tables, pictures, or videos will be accepted. Have the presenter CV and signed COI form in pdf format ready to upload when you initiate abstract submission to facilitate the submission process.

Link to submit and Abstract: https://mhsrs.amedd.army.mil/SitePages/Submit-an-Abstract.aspx

Recent News

03/12/2026

Quoin Pharmaceuticals Announces FDA Grants Fast Track Designation for QRX003 for the Treatment of Netherton Syndrome

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to QRX003 lotion (4%) for the treatment of Netherton Syndrome, a rare

03/11/2026

ATCC Secures NIAID Contract to Strengthen U.S. Preparedness Against Emerging Infectious Diseases

ATCC has been awarded an Indefinite Delivery/Indefinite Quantity (IDIQ) contract (number 75N93025D00017) with an ordering period of 7 years with Federal funds from the National Institute of Allergy and Infectious Diseases (NIAID), an institute within the National Institutes of Health (NIH) and the Department of Health and Human Services (HHS). The contract, with an initial

03/10/2026

ivWatch and Aon Address Costly and Underreported Patient Harm Epidemic with New Return on Investment Model

ivWatch, the IV safety company, has partnered with Aon, a leading global insurance broker and risk consultant, to quantify the clinical and financial impact of severe IV infiltration and extravasation injuries – one of the most underreported and costly adverse events in healthcare – and to model the return on investment associated with detecting these